Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SEPT6
REST API REST API
Homo sapiens
SEPT6 is differentially expressed in 400 experiments: 186 organism parts: brain, thymus, ... (184 more);, 316 disease states: normal, acute myeloid leukemia, ... (314 more);, 169 cell types 617 cell lines 52 compound treatments and 85 other conditions.
Synonyms SEP2, MGC20339, MGC16619, SEPT2, KIAA0128
Orthologs F1NLX2_CHICK (Gallus gallus)   sept6 (Danio rerio)   SEPT6_BOVIN (Bos taurus)   Sept6 (Rattus norvegicus)   Sept6 (Mus musculus)   F6V5P8_CIOIN (Ciona intestinalis)   CDC3 (Saccharomyces cerevisiae)   Sep2 (Drosophila melanogaster)   Sep5 (Drosophila melanogaster)   sept6 (Xenopus laevis)   SEPT6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cleavage furrow, cytoskeleton, cytoplasm, condensed chromosome kinetochore, synaptic vesicle, GTP binding, cell cycle, midbody, spindle, septin complex, cytokinesis, axon terminus, nucleotide binding, cellular_component, chromosome, interspecies interaction between organisms
InterPro Term Septin, Cell_div_GTP-bd
UniProt Accession Q541S4, Q548C9, Q14141, B4E049, B1AMS2, F5H1J5, F8W8Q8
Search EB-eye ENSG00000125354
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7224, E-GEOD-7540, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
SW480
3
E-GEOD-18005, E-MTAB-37, E-GEOD-2509
AGS
2
E-MTAB-37, E-GEOD-15460
611 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (73 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
adipocyte
1
2
E-AFMX-5, E-TABM-145, E-MTAB-25
nucleus pulposus
1
E-MEXP-2488
163 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (83 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-GEOD-96, E-MTAB-37, E-MTAB-62
glioblastoma
1
4
E-GEOD-4290, E-MTAB-62, E-MTAB-37, E-GEOD-4412, E-MEXP-567 ... (5 experiments)
control
1
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20295, E-GEOD-20168 ... (5 experiments)
chronic lymphocytic leukemia
3
E-GEOD-2466, E-MTAB-37, E-GEOD-6691
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
colorectal adenocarcinoma
3
E-AFMX-5, E-MTAB-62, E-MTAB-37
310 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-2639, E-GEOD-5741, ... (35 experiments)

Factor Value U/D Experiments
none
6
9
E-GEOD-5824, E-GEOD-4600, E-TABM-868, E-MEXP-1958, E-GEOD-412, ... (15 experiments)
lipopolysaccharide
3
E-GEOD-3720, E-TABM-868, E-MEXP-1958
control
2
E-GEOD-2639, E-GEOD-3284
ethanol
2
E-MEXP-2241, E-GEOD-3113
actinomycin D
1
E-GEOD-6400
5-fluorouridine
1
1
E-GEOD-995
46 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-17189, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, ... (12 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-1045, E-TABM-1029, E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, ... (19 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-21612, E-MEXP-2657, E-GEOD-20540, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-1956, E-GEOD-2466, ... (47 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-4525, E-GEOD-19703, E-GEOD-22152, ... (11 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-8052, E-GEOD-7540, ... (8 experiments)

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561

Processing time: 0.406 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM